1,277 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
NVS Novartis AG $85.13 $197.65B N/A
Article Searches
Novartis (NVS) Launches Zarxio: First Biosimilar in the U.S. http://www.zacks.com/stock/news/188907/novartis-nvs-launches-zarxio-first-biosimilar-in-the-us?cid=CS-ZC-FT-188907 Sep 03, 2015 - Novartis (NVS) launched Zarxio (biosimilar version of Amgen's Neupogen) in the U.S., which became the first FDA-approved biosimilar to be launched in the country.
Amgen, Novartis Team Up; Bone Drug Positive in Phase III http://www.zacks.com/stock/news/188757/amgen-novartis-team-up-bone-drug-positive-in-phase-iii?cid=CS-ZC-FT-188757 Sep 02, 2015 - Amgen (AMGN) inks deal with Novartis for Alzheimer's disease and migraine; reports positive phase III data on romosozumab.
Pfizer (PFE) Gains on Label Expansion Efforts for Ibrance http://www.zacks.com/stock/news/188221/pfizer-pfe-gains-on-label-expansion-efforts-for-ibrance?cid=CS-ZC-FT-188221 Aug 28, 2015 - Pfizer (PFE) commenced a phase III study (PALLAS) on Ibrance in early-stage breast cancer patients.
Novartis' (NVS) Promacta Label Further Expanded in U.S. http://www.zacks.com/stock/news/187863/novartis-nvs-promacta-label-further-expanded-in-us?cid=CS-ZC-FT-187863 Aug 26, 2015 - Novartis (NVS) with partner Ligand (LGND) announced that the FDA has approved the use of Promacta in children between 1 to 6 years of age with chronic ITP.
Why Euronav NV (EURN) Could Beat Earnings Estimates Again http://www.zacks.com/stock/news/187731/euronav-nv-in-the-shipping-transportation-industry-could-be-a-great-candidate-for-another-beat?cid=CS-ZC-FT-187731 Aug 26, 2015 - Euronav NV in the Shipping Transportation industry could be a great candidate for another beat as recent estimates have been moving higher for the company, while the Earnings ESP for EURN is positive, which is a great sign of a coming beat.
Novartis to Buy Full Arzerra Rights from GlaxoSmithKline http://www.zacks.com/stock/news/187507/novartis-to-buy-full-arzerra-rights-from-glaxosmithkline?cid=CS-ZC-FT-187507 Aug 24, 2015 - Novartis (NVS) inked a deal with GlaxoSmithKline to acquire all remaining rights to Arzerra for up to $1 billion plus royalties.
QUAD GRAPHICS (QUAD) - Profit Tracks http://www.zacks.com/research/screening/tracks/highlight.php?id=4948&cid=CS-ZC--4948 Apr 26, 2012 - QUAD GRAPHICS

Pages: 1...123124125126127128

<<<Page 128